Braiin Limited is the presenting partner of the Defence Robotics & Counter-UAS Congress at Global Drone 2026 in Australia, showcasing its role in advancing autonomous defence technologies. The event features keynotes and panels on counter-UAS, sovereign robotics, and critical infrastructure protection, with Braiin's Head of AI and Robotics, Rob Sutton, leading discussions. This partnership strengthens Braiin's position in the defence and critical infrastructure sectors, complementing its AI platform and agricultural drone capabilities. The event runs from November 11-13, 2026, attracting global industry and government leaders.
Braiin's role in defence robotics and counter-UAS technology is presented here with a snapshot of related Technology-sector stocks on Pluang as of Nov 10, 2026 20:03 WIB. Among 150 priced US tech stocks, 40 rose and 101 fell today. ASX gained 4.77% to USD 36.00 with a longer typical hold time of 50 days and a buy majority of 57%, contrasting with CIFR and AEHR which fell 4.85% and 4.33% respectively, and had shorter hold times of 17 days each, with CIFR favored by buyers at 66% and AEHR slightly more sold at 53%.
project44 has partnered with Snowflake to enhance supply chain decision-making through Mo, an AI-powered supply chain analyst. Mo uses project44's extensive logistics data and Snowflake Cortex AI to provide accurate, consistent answers to complex sup...
H&R Block has launched the Emerald Advance Loan, a fixed-rate short-term loan up to $1,750 with a 35.90% APR, designed to help families cover year-end expenses without monthly payments. Borrowers repay the loan in full by March 31, 2027, with no impa...
Duke Robotics has entered a strategic collaboration with Greek security firm CRONOS to commercialize its Insulator Cleaning Drone (IC Drone) technology in Greece. This partnership leverages CRONOS's strong presence in Greece's critical infrastructure...
Alm. Brand A/S repurchased 1,369,397 shares between November 3 and 9, 2026, at an average price of DKK 17.46 per share. This is part of their announced buy-back program totaling up to DKK 593 million, aiming to reduce the number of outstanding shares...
Novartis has secured first place in the 2026 Access to Medicine Index, maintaining its lead since 2024 by excelling across all assessed technical areas, including governance, R&D, and product delivery. The company scored 3.86 out of 5 overall, with a...
